Article ; Online: Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure.
The New England journal of medicine
2023 Volume 389, Issue 8, Page(s) 700–709
Abstract: Background: Several studies have suggested that patients with kidney failure may benefit from high-dose hemodiafiltration as compared with standard hemodialysis. However, given the limitations of the various published studies, additional data are needed. ...
Abstract | Background: Several studies have suggested that patients with kidney failure may benefit from high-dose hemodiafiltration as compared with standard hemodialysis. However, given the limitations of the various published studies, additional data are needed. Methods: We conducted a pragmatic, multinational, randomized, controlled trial involving patients with kidney failure who had received high-flux hemodialysis for at least 3 months. All the patients were deemed to be candidates for a convection volume of at least 23 liters per session (as required for high-dose hemodiafiltration) and were able to complete patient-reported outcome assessments. The patients were assigned to receive high-dose hemodiafiltration or continuation of conventional high-flux hemodialysis. The primary outcome was death from any cause. Key secondary outcomes were cause-specific death, a composite of fatal or nonfatal cardiovascular events, kidney transplantation, and recurrent all-cause or infection-related hospitalizations. Results: A total of 1360 patients underwent randomization: 683 to receive high-dose hemodiafiltration and 677 to receive high-flux hemodialysis. The median follow-up was 30 months (interquartile range, 27 to 38). The mean convection volume during the trial in the hemodiafiltration group was 25.3 liters per session. Death from any cause occurred in 118 patients (17.3%) in the hemodiafiltration group and in 148 patients (21.9%) in the hemodialysis group (hazard ratio, 0.77; 95% confidence interval, 0.65 to 0.93). Conclusions: In patients with kidney failure resulting in kidney-replacement therapy, the use of high-dose hemodiafiltration resulted in a lower risk of death from any cause than conventional high-flux hemodialysis. (Funded by the European Commission Research and Innovation; CONVINCE Dutch Trial Register number, NTR7138.). |
|||||
---|---|---|---|---|---|---|
MeSH term(s) | Humans ; Hemodiafiltration/adverse effects ; Hemodiafiltration/methods ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/therapy ; Renal Dialysis/adverse effects ; Renal Insufficiency/etiology ; Treatment Outcome | |||||
Language | English | |||||
Publishing date | 2023-06-16 | |||||
Publishing country | United States | |||||
Document type | Journal Article ; Pragmatic Clinical Trial ; Randomized Controlled Trial | |||||
ZDB-ID | 207154-x | |||||
ISSN | 1533-4406 ; 0028-4793 | |||||
ISSN (online) | 1533-4406 | |||||
ISSN | 0028-4793 | |||||
DOI | 10.1056/NEJMoa2304820 | |||||
Shelf mark |
|
|||||
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.34: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.